Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Hospital-acquired infection wikipedia , lookup
Autoimmune encephalitis wikipedia , lookup
Pathophysiology of multiple sclerosis wikipedia , lookup
Sjögren syndrome wikipedia , lookup
Management of multiple sclerosis wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Multiple sclerosis research wikipedia , lookup
Declining renal function in idiopathic membranous nephropathy: a report from Two Tertiary London Renal Units Background Idiopathic Membranous Nephropathy (IMN) is a major cause of the nephrotic syndrome in adults. Renal function may deteriorate (progressor) or be preserved (non-progressor patients) Methods We performed a retrospective analysis of all patients with biopsy proven IMN under follow up over the last 20 years. Results We identified 188 patients that had biopsy proven IMN under follow up during 1995-2015. Median age Male % Ethnicity (White / Black / Asian / Unknown) % Diagnosis Serum creatinine (sCr) (µmol/L) Diagnosis Serum albumin (sAlb) (mmol/L) Diagnosis urine protein creatinine ratio (PCR) (mg/mmol) Spontaneous remission % Renal replacement therapy (RRT) % Deceased % 58 (44-71) 68 48 / 17 / 24 / 11 86.5 (64 – 111) 25 ± 7 900 (485 – 1255) 34 34 12 Of the 37 patients that spontaneously remitted, 5% relapsed. 20% of patients were progressors (increase in sCr >50%, not on RRT). There was no statistical difference between sCr (101 ± 6 vs 92 ± 9 µmol/L, ns), sAlb (25.2 ± 1.3 vs 26.2 ± 0.8 mmol/L, ns) or PCR (893 ± 87 vs 895 ± 94 mg/mmol, ns) at diagnosis between progressors and non-progressors respectively. Progressors were more likely to be Asian (36% vs 21%, p=0.058) and non-progressors black (32% vs 20%, p=0.058). 65% of patients were treated with immunosuppressives. 60% received prednisolone, the most frequently used first line agent was cyclophosphamide 35%, followed by anti-proliferative agents 34% and calcineurin inhibitors (CNI) 23%. There was a significant difference between treatment between progressors and non-progressors. Progressors were more likely to be treated with CNI (38% vs 15%, p=0.04) The complication rate from immunosuppression was 25%. The most common was diabetes from steroid therapy at 10%. Infection occurred in 2% and drug specific complications in 7%. Thromboembolism rate from nephrosis was low at 14%. Conclusion At diagnosis there was no significant difference in sCr, sAlb or PCR between progressors and non-progressors. Progressor patients with IMN may benefit from immunosuppression, but this is associated with risks. In our cohort, the Asian population were more likely to be progressors. This differs to current published data, possibly due to the predominance of Indian subcontinent population. It is important to accurately identify progressor patients; there is an unmet need for a biomarker to do this.